相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Effects of Metformin Versus Glipizide on Cardiovascular Outcomes in Patients With Type 2 Diabetes and Coronary Artery Disease
Jie Hong et al.
DIABETES CARE (2013)
Dipeptidyl peptidase-4 inhibitors and cardiovascular risk: a meta-analysis of randomized clinical trials
M. Monami et al.
DIABETES OBESITY & METABOLISM (2013)
Incretin-based therapies and cardiovascular risk
Edoardo Mannucci et al.
CURRENT MEDICAL RESEARCH AND OPINION (2012)
Exenatide twice daily versus glimepiride for prevention of glycaemic deterioration in patients with type 2 diabetes with metformin failure (EUREXA): an open-label, randomised controlled trial
Baptist Gallwitz et al.
LANCET (2012)
2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial
Baptist Gallwitz et al.
LANCET (2012)
Basal Insulin and Cardiovascular and Other Outcomes in Dysglycemia
Hertzel C. Gerstein et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Addition of either pioglitazone or a sulfonylurea in type 2 diabetic patients inadequately controlled with metformin alone: Impact on cardiovascular events. A randomized controlled trial
O. Vaccaro et al.
NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES (2012)
Safety of dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized clinical trials
Matteo Monami et al.
CURRENT MEDICAL RESEARCH AND OPINION (2011)
Dapagliflozin Versus Glipizide as Add-on Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control With Metformin A randomized, 52-week, double-blind, active-controlled noninferiority trial
Michael A. Nauck et al.
DIABETES CARE (2011)
Efficacy and safety of treatment with sitagliptin or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy: a randomized, double-blind, non-inferiority trial
R. Arechavaleta et al.
DIABETES OBESITY & METABOLISM (2011)
Effect of metformin on cardiovascular events and mortality: a meta-analysis of randomized clinical trials
C. Lamanna et al.
DIABETES OBESITY & METABOLISM (2011)
Pioglitazone delays proximal tubule dysfunction and improves cerebral vessel endothelial dysfunction in normoalbuminuric people with type 2 diabetes mellitus
Ligia Petrica et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2011)
Exenatide or glimepiride added to metformin on metabolic control and on insulin resistance in type 2 diabetic patients
Giuseppe Derosa et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2011)
Pioglitazone Compared to Glibenclamide on Lipid Profile and Inflammation Markers in Type 2 Diabetic Patients During an Oral Fat Load
G. Derosa et al.
HORMONE AND METABOLIC RESEARCH (2011)
Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials
Remy Boussageon et al.
BMJ-BRITISH MEDICAL JOURNAL (2011)
Effect of Rosiglitazone on Progression of Coronary Atherosclerosis in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease
Hertzel C. Gerstein et al.
CIRCULATION (2010)
Pioglitazone in addition to metformin improves erythrocyte deformability in patients with Type 2 diabetes mellitus
Thomas Forst et al.
CLINICAL SCIENCE (2010)
Efficacy and safety of the once-daily human GLP-1 analogue, liraglutide, vs glibenclamide monotherapy in Japanese patients with type 2 diabetes
Y. Seino et al.
CURRENT MEDICAL RESEARCH AND OPINION (2010)
Exenatide Versus Glibenclamide in Patients with Diabetes
G. Derosa et al.
DIABETES TECHNOLOGY & THERAPEUTICS (2010)
A comparison of efficacy and safety of vildagliptin and gliclazide in combination with metformin in patients with Type 2 diabetes inadequately controlled with metformin alone: a 52-week, randomized study
C. Filozof et al.
DIABETIC MEDICINE (2010)
Effects of One Year Treatment of Vildagliptin Added to Pioglitazone or Glimepiride in Poorly Controlled Type 2 Diabetic Patients
G. Derosa et al.
HORMONE AND METABOLIC RESEARCH (2010)
Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2-year study
T. Seck et al.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2010)
Saxagliptin is non-inferior to glipizide in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: a 52-week randomised controlled trial
B. Goke et al.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2010)
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
David Moher et al.
ANNALS OF INTERNAL MEDICINE (2009)
Pioglitazone vs glimepiride: Differential effects on vascular endothelial function in patients with type 2 diabetes
Katerina Papathanassiou et al.
ATHEROSCLEROSIS (2009)
Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy
E. Ferrannini et al.
DIABETES OBESITY & METABOLISM (2009)
Liver Safety in Patients with Type 2 Diabetes Treated with Pioglitazone Results from a 3-Year, Randomized, Comparator-Controlled Study in the US
Keith G. Tolman et al.
DRUG SAFETY (2009)
Efficacy and Safety Comparison Between the DPP-4 Inhibitor Vildagliptin and the Sulfonylurea Gliclazide After Two Years of Monotherapy in Drug-naive Patients with Type 2 Diabetes
J. E. Foley et al.
HORMONE AND METABOLIC RESEARCH (2009)
Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial
Alan Garber et al.
LANCET (2009)
Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial
Philip D. Home et al.
LANCET (2009)
Impact of rosiglitazone and glyburide on nitrosative stress and myocardial blood flow regulation in type 2 diabetes mellitus
Rodica Pop-Busui et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2009)
Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 60's study
Giuseppe Derosa et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2009)
Prevention of cardiovascular disease through glycemic control in type 2 diabetes: A meta-analysis of randomized clinical trials
E. Mannucci et al.
NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES (2009)
Nephro- and neuroprotective effects of rosiglitazone versus glimepiride in normoalbuminuric patients with type 2 diabetes mellitus: a randomized controlled trial
Ligia Petrica et al.
WIENER KLINISCHE WOCHENSCHRIFT (2009)
Rosiglitazone produces a greater reduction in circulating platelet activity compared with gliclazide in patients with type 2 diabetes mellitus -: An effect probably mediated by direct platelet PPARγ activation
M. P. Khanolkar et al.
ATHEROSCLEROSIS (2008)
Improvement of glycaemic and lipid profiles with muraglitazar plus metformin in patients with type 2 diabetes: an active-control trial with glimepiride
Cindy J. Rubin et al.
DIABETES & VASCULAR DISEASE RESEARCH (2008)
Rosiglitazone-associated fractures in type 2 diabetes - An analysis from a diabetes outcome progression trial (ADOPT)
Steven E. Kahn et al.
DIABETES CARE (2008)
Initial treatment with fixed-dose combination rosiglitazone/glimepiride in patients with previously untreated type 2 diabetes
H. S. Chou et al.
DIABETES OBESITY & METABOLISM (2008)
Comparison of gliclazide with insulin as initial treatment modality in newly diagnosed type 2 diabetes
Satish T. Chandra et al.
DIABETES TECHNOLOGY & THERAPEUTICS (2008)
Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes -: The PERISCOPE randomized controlled trial
Steven E. Nissen et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2008)
Pioglitazone and heart failure: Results from a controlled study in patients with type 2 diabetes mellitus and systolic dysfunction
Thomas D. Giles et al.
JOURNAL OF CARDIAC FAILURE (2008)
Comparison of fixed-dose rosiglitazone/metformin combination therapy with sulphonylurea plus metformin in overweight individuals with type 2 diabetes inadequately controlled on metformin alone
A. Hamann et al.
EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES (2008)
Adiponectin mediates the suppressive effect of rosiglitazone on plasminogen activator inhibitor-1 production
Ruby L. C. Hoo et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2007)
Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus - A meta-analysis of randomized trials
A. Michael Lincoff et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2007)
Thiazolidinedione increases serum soluble receptor for advanced glycation end-products in type 2 diabetes
K. C. B. Tan et al.
DIABETOLOGIA (2007)
Nateglinide or gliclazide in combination with metformin for treatment of patients with type 2 diabetes mellitus inadequately controlled on maximum doses of metformin alone: 1-year trial results
S. Ristic et al.
DIABETES OBESITY & METABOLISM (2007)
Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes
Steven E. Nissen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Glimepiride versus metformin as monotherapy in pediatric patients with type 2 diabetes - A randomized, single-blind comparative study
Michael Gottschalk et al.
DIABETES CARE (2007)
Effects of nateglinide and glibenclamide on prothrombotic factors in naive type 2 diabetic patients treated with metformin: A 1-year, double-blind, randomized clinical trial
Giuseppe Derosa et al.
INTERNAL MEDICINE (2007)
Recognition of fasting or overall hyperglycaemia when starting insulin treatment in patients with type 2 diabetes in general practice
Markku Vaehaetalo et al.
SCANDINAVIAN JOURNAL OF PRIMARY HEALTH CARE (2007)
Effects of pioglitazone hydrochloride on Japanese patients with type 2 diabetes mellitus
Tamio Teramoto et al.
JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS (2007)
Rosiglitazone improves endothelial function and inflammation but not asymmetric dimethylarginine or oxidative stress in patients with type 2 diabetes mellitus
Aaron S. Kelly et al.
VASCULAR MEDICINE (2007)
A one-year study comparing the efficacy and safety of rosiglitazone and glibenclamide in the treatment of type 2 diabetes
Markolf Hanefeld et al.
NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES (2007)
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy
Steven E. Kahn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes - A randomized trial
Theodore Mazzone et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2006)
Three-year mortality in diabetic patients treated with different combinations of insulin secretagogues and metformin
Matteo Monami et al.
DIABETES-METABOLISM RESEARCH AND REVIEWS (2006)
Rosiglitazone reduces microalbuminuria and blood pressure independently of glycemia in type 2 diabetes patients with microalbuminuria
George L. Bakris et al.
JOURNAL OF HYPERTENSION (2006)
Long-term safety of pioglitazone versus glyburide in patients with recently diagnosed type 2 diabetes mellitus
Rajeev Jain et al.
PHARMACOTHERAPY (2006)
Effect of pioglitazone on urinary liver-type fatty acid-binding protein concentrations in diabetes patients with microalbuminuria
Tsukasa Nakamura et al.
DIABETES-METABOLISM RESEARCH AND REVIEWS (2006)
An open, randomized, parallel-group study to compare the efficacy and safety profile of inhaled human insulin (Exubera) with glibenclamide as adjunctive therapy in patients with type 2 diabetes poorly controlled on metformin
Anthony H. Barnett et al.
DIABETES CARE (2006)
Postprandial plasma glucose excursions and cognitive functioning in aged type 2 diabetics
A. M. Abbatecola et al.
NEUROLOGY (2006)
Sulfonylureas and the risk of myocardial infarction
Henriette Thisted et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2006)
Glimepiride versus pioglitazone combination therapy in subjects with type 2 diabetes inadequately controlled on metformin monotherapy: results of a randomized clinical trial
Guillermo Umpierrez et al.
CURRENT MEDICAL RESEARCH AND OPINION (2006)
Comparison of glycaemic control over 1 year with pioglitazone or gliclazide in patients with Type 2 diabetes
G Perriello et al.
DIABETIC MEDICINE (2006)
Metformin-glibenclamide versus metformin plus rosiglitazone in patients with type 2 diabetes inadequately controlled on metformin monotherapy
A Garber et al.
DIABETES OBESITY & METABOLISM (2006)
Improving metabolic control leads to better working memory in adults with type 2 diabetes
CM Ryan et al.
DIABETES CARE (2006)
Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events):: a randomised controlled trial
JA Dormandy et al.
LANCET (2005)
Triple therapy with glimepiride in patients with type 2 diabetes mellitus inadequately controlled by metformin and a thiazolidinedione: Results of a 30-week, randomized, double-blind, placebo-controlled, parallel-group study
VL Roberts et al.
CLINICAL THERAPEUTICS (2005)
Two-year efficacy and safety of initial combination therapy with nateglinide or glyburide plus metformin
J Gerich et al.
DIABETES CARE (2005)
Long-term effects of glimepiride or rosiglitazone in combination with metformin on blood pressure control in type 2 diabetic patients affected by the metabolic syndrome: A 12-month, double-blind, randomized clinical trial
G Derosa et al.
CLINICAL THERAPEUTICS (2005)
Comparison of metabolic effects of pioglitazone, metformin, and glimepiride over 1 year in Japanese patients with newly diagnosed Type 2 diabetes
T Yamanouchi et al.
DIABETIC MEDICINE (2005)
Pharmacological PPARγ stimulation in contrast to beta cell stimulation results in an improvement in adiponectin and proinsulin intact levels and reduces intima media thickness in patients with type 2 diabetes
T Forst et al.
HORMONE AND METABOLIC RESEARCH (2005)
Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control -: Results from the pioneer study
A Pfützner et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2005)
Effect of pioglitazone on arteriosclerosis in comparison with that of glibenclamide
I Watanabe et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2005)
Comparison of pioglitazone and gliclazide in sustaining glycemic control over 2 years in patients with type 2 diabetes
MH Tan et al.
DIABETES CARE (2005)
Long-term therapy with addition of pioglitazone to metformin compared with the addition of gliclazide to metformin in patients with type 2 diabetes: a randomized, comparative study
DR Matthews et al.
DIABETES-METABOLISM RESEARCH AND REVIEWS (2005)
Pioglitazone elicits long-term improvements in insulin sensitivity in patients with type 2 diabetes: comparisons with gliclazide-based regimens
B Charbonnel et al.
DIABETOLOGIA (2005)
Sustained effects of pioglitazone vs. glibenclamide on insulin sensitivity, glycaemic control, and lipid profiles in patients with Type 2 diabetes
MH Tan et al.
DIABETIC MEDICINE (2004)
Regression of carotid atherosclerosis by control of postprandial hyperglycemia in type 2 diabetes mellitus
K Esposito et al.
CIRCULATION (2004)
Results of a randomized, double-blind, placebo-controlled study administering glimepiride to patients with type 2 diabetes mellitus inadequately controlled with rosiglitazone monotherapy
D McCluskey et al.
CLINICAL THERAPEUTICS (2004)
Effect of pioglitazone on carotid intima-media thickness and arterial stiffness in type 2 diabetic nephropathy patients
T Nakamura et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2004)
Effects of pioglitazone and glimepiride on glycemic control and insulin sensitivity in Mexican patients with type 2 diabetes mellitus:: A multicenter, randomized, double-blind, parallel-group trial
M Tan et al.
CLINICAL THERAPEUTICS (2004)
Is acarbose equivalent to tolbutamide as first treatment for newly diagnosed type 2 diabetes in general practice? A randomised controlled trial
FA van de Laar et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2004)
Combination treatment with metformin and glibenclamide versus single-drug therapies in type 2 diabetes mellitus: A randomized, double-blind, comparative study
F Tosi et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2003)
Metabolic effects of mealtime insulin lispro in comparison to glibenclamide in early type 2 diabetes
T Forst et al.
EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES (2003)
Combined bedtime insulin -: daytime sulphonylurea regimen compared with two different daily insulin regimens in type 2 diabetes:: effects on HbA1c and hypoglycaemia rate -: a randomised trial
MHA Stehouwer et al.
DIABETES-METABOLISM RESEARCH AND REVIEWS (2003)
Comparison between repaglinide and glimepiride in patients with type 2 diabetes mellitus: A one-year, randomized, double-blind assessment of metabolic parameters and cardiovascular risk factors
G Derosa et al.
CLINICAL THERAPEUTICS (2003)
A comparison of the effects of rosiglitazone and glyburide on cardiovascular function and glycemic control in patients with type 2 diabetes
MS Sutton et al.
DIABETES CARE (2002)
Effects of treatment with sulfonylurea drugs or insulin on ischemia-induced myocardial dysfunction in type 2 diabetes
R Scognamiglio et al.
DIABETES (2002)
Comparison between repaglinide and glipizide in Type 2 diabetes mellitus: a 1-year multicentre study
S Madsbad et al.
DIABETIC MEDICINE (2001)
Effect of troglitazone on urinary albumin excretion and serum type IV collagen concentrations in Type 2 diabetic patients with microalbuminuria or macroalbuminuria
T Nakamura et al.
DIABETIC MEDICINE (2001)
Concentration of the complement activation product, acylation-stimulating protein, is related to C-reactive protein in patients with type 2 diabetes
P Ebeling et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2001)
Comparison of acarbose and gliclazide as first-line agents in patients with type 2 diabetes
S Salman et al.
CURRENT MEDICAL RESEARCH AND OPINION (2001)
分享论文
